Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients
- 186 Downloads
Genetic polymorphisms of thymidylate synthase (TYMS) gene have been reported to be associated with development or prognosis of several cancers. However, the association between polymorphisms of TYMS gene and clinical outcomes of non-small cell lung cancer (NSCLC) patients are still unknown. In the present study, we investigated the associations between single nucleotide polymorphisms (SNPs) of TYMS gene and response to chemotherapy as well as clinical outcomes in NSCLC patients. Five SNPs in TYMS gene were genotyped using the Sequenom iPLEX genotyping system in a hospital-based cohort with 500 NSCLC patients, and their associations with NSCLC outcomes were evaluated by Cox proportional hazard regression analysis under three genetic models (additive, dominant, and recessive models). Our data showed that there was no significant association between individual SNP and overall survival of NSCLC patients. However, SNP rs2847153 was significantly associated with NSCLC recurrence under recessive model. We further identified a significant interaction between rs2847153 and chemotherapy in modifying clinical outcome of patients. Our data showed that individuals carrying GG/GA genotypes of rs2847153 had a significantly better response to chemotherapy when comparing to those carrying AA genotype. Conclusively, our data suggest that SNPs rs2847153 in TYMS gene may be a potential biomarker for predicting clinical outcome and personalized treatment in NSCLC patients.
KeywordsThymidylate synthase Non-small cell lung cancer Single nucleotide polymorphisms Prognosis
This work was supported by Program for New Century Excellent Talents in University and National Basic Research Program (2015CB553703).
- 7.Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3543–51. doi: 10.1200/JCO.2007.15.0375.CrossRefGoogle Scholar
- 8.Tahara E, Yasui W, Ito H, Harris CC. Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities’ Consortium International Symposium, November 2009. Jpn J Clin Oncol. 2010;40(7):702–8. doi: 10.1093/jjco/hyq031.CrossRefPubMedGoogle Scholar
- 13.Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74(1):132–8. doi: 10.1016/j.lungcan.2011.01.024.CrossRefPubMedGoogle Scholar
- 14.Wang X, Wang Y, Cheng J, Ha M. Association of thymidylate synthase gene 3’-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci. 2013;20:5. doi: 10.1186/1423-0127-20-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Arevalo E, Castanon E, Lopez I, Salgado J, Collado V, Santisteban M, et al. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. J Transl Med. 2014;12:98. doi: 10.1186/1479-5876-12-98.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer J Int Cancer. 2003;104(6):790–5. doi: 10.1002/ijc.11014.CrossRefGoogle Scholar
- 31.Grimminger PP, Schneider PM, Metzger R, Vallbohmer D, Holscher AH, Danenberg PV, et al. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer. 2010;11(5):328–34. doi: 10.3816/CLC.2010.n.041.CrossRefPubMedGoogle Scholar
- 32.Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, Kenzaki K, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res. 2007;27(4C):2641–8.PubMedGoogle Scholar
- 33.Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, et al. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res. 2012;32(10):4589–96.PubMedGoogle Scholar